X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bay-43-9006 (231) 231
humans (209) 209
niacinamide - analogs & derivatives (182) 182
index medicus (157) 157
sorafenib (149) 149
oncology (147) 147
phenylurea compounds (134) 134
male (104) 104
female (94) 94
cancer (88) 88
middle aged (86) 86
raf kinase (85) 85
aged (78) 78
pyridines - therapeutic use (76) 76
benzenesulfonates - therapeutic use (75) 75
refractory solid tumors (73) 73
antineoplastic agents - therapeutic use (66) 66
pharmacokinetics (65) 65
adult (57) 57
antitumor-activity (55) 55
pharmacology & pharmacy (55) 55
animals (54) 54
phase-i (54) 54
factor receptor inhibitor (51) 51
apoptosis (50) 50
benzenesulfonates - adverse effects (49) 49
pyridines - adverse effects (49) 49
angiogenesis (48) 48
antineoplastic agents - pharmacology (46) 46
cell line, tumor (46) 46
pyridines - pharmacology (46) 46
antineoplastic agents - adverse effects (45) 45
down-regulation (45) 45
safety (45) 45
treatment outcome (43) 43
benzenesulfonates - pharmacology (42) 42
raf/mek/erk pathway (42) 42
aged, 80 and over (41) 41
protein kinase inhibitors - therapeutic use (40) 40
days on/7 days (38) 38
antineoplastic agents (37) 37
liver neoplasms - drug therapy (37) 37
pyridines - administration & dosage (37) 37
antimitotic agents (36) 36
benzenesulfonates - administration & dosage (35) 35
kinase (35) 35
multikinase inhibitor (35) 35
carcinoma, hepatocellular - drug therapy (34) 34
inhibitor bay-43-9006 (34) 34
apoptosis - drug effects (32) 32
carcinoma, renal cell - drug therapy (32) 32
mice (32) 32
renal-cell carcinoma (32) 32
kidney neoplasms - drug therapy (31) 31
neoplasms - drug therapy (31) 31
therapy (31) 31
care and treatment (29) 29
dose-response relationship, drug (29) 29
growth (29) 29
medicine & public health (29) 29
pyridines - pharmacokinetics (29) 29
antineoplastic agents - administration & dosage (28) 28
benzenesulfonates - pharmacokinetics (28) 28
carcinoma (28) 28
hepatocellular carcinoma (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
cell proliferation - drug effects (27) 27
endothelial growth-factor (27) 27
inhibitor (26) 26
protein kinase inhibitors - pharmacology (25) 25
progression (24) 24
protein kinase inhibitors - administration & dosage (24) 24
antineoplastic agents - pharmacokinetics (23) 23
article (23) 23
pharmacology/toxicology (23) 23
phenylurea compounds - administration & dosage (23) 23
niacinamide - administration & dosage (22) 22
protein kinase inhibitors - adverse effects (22) 22
carcinoma, hepatocellular - pathology (21) 21
combination (21) 21
drug therapy (21) 21
liver neoplasms - pathology (21) 21
neoplasms (21) 21
pathway (21) 21
research (21) 21
solid tumors (20) 20
tumors (20) 20
bevacizumab (19) 19
mcl-1 (19) 19
chemotherapy (18) 18
digestive system diseases (18) 18
liver cancer (18) 18
prognosis (18) 18
survival (18) 18
disease-free survival (17) 17
lung neoplasms - drug therapy (17) 17
mice, nude (17) 17
hepatoma (16) 16
melanoma (16) 16
niacinamide - adverse effects (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 06/2006, Volume 24, Issue 16, pp. 2505 - 2512
Purpose This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and... 
FACTOR RECEPTOR INHIBITOR | DESIGN | BAY-43-9006 | PHARMACOKINETICS | ONCOLOGY | SAFETY | DAYS ON/7 DAYS | RAF KINASE | REFRACTORY SOLID TUMORS | WITHDRAWAL | HUMAN CANCER
Journal Article
CANCER CELL, ISSN 1535-6108, 07/2007, Volume 12, Issue 1, pp. 66 - 80
Cells expressing oncogenic c-Myc are sensitized to TNF superfamily proteins. c-Myc also is an important factor in determining whether a cell is sensitive to... 
CYTOCHROME-C | PHOSPHATIDYLINOSITOL 3-KINASE/AKT | SIGNALING PATHWAYS | ONCOLOGY | INDUCED APOPTOSIS | DOWN-REGULATION | TNF-ALPHA | INDUCTION | MEDIATED INHIBITION | NF-KAPPA-B | INHIBITOR BAY-43-9006
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 14, pp. 2117 - 2127
Journal Article
Cancer Research, ISSN 0008-5472, 11/2010, Volume 70, Issue 22, pp. 9309 - 9318
Markers that could accurately predict responses to the general kinase inhibitor sorafenib are needed to better leverage its clinical applications. In this... 
HEMATOPOIETIC-CELLS | P38 ACTIVATION | ONCOLOGY | LIVER-REGENERATION | STRESS-INDUCED APOPTOSIS | DOWN-REGULATION | HUMAN HCC | CANCER | EXPRESSION | MULTIKINASE INHIBITOR | INHIBITOR BAY-43-9006
Journal Article
ACTA ONCOLOGICA, ISSN 0284-186X, 2008, Volume 47, Issue 2, pp. 176 - 186
Background. Hand-foot skin reaction (HFSR) is a dose-limiting toxicity associated with sorafenib, an oral multi-kinase inhibitor with clinical activity against... 
ADVANCED SOLID TUMORS | BAY-43-9006 | ONCOLOGY | CLINICAL-TRIALS | SUNITINIB | C-KIT | KINASE INHIBITORS | KIT-LIGAND | PHASE-I | RENAL-CELL CARCINOMA | PYRIDOXINE THERAPY
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 08/2006, Volume 108, Issue 4, pp. 1374 - 1376
The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib.... 
IN-VITRO | MYELOPROLIFERATIVE DISEASE | BAY-43-9006 | THERAPY | FUSION | RAF KINASE | IDIOPATHIC HYPEREOSINOPHILIC SYNDROME | KINASE INHIBITORS | REFRACTORY SOLID TUMORS | HEMATOLOGY | CANCER
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 26, pp. 4293 - 4300
Purpose This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity,... 
BAY-43-9006 | HEPATITIS-C VIRUS | TUMOR PROGRESSION | ONCOLOGY | KINASE | DOXORUBICIN | GENE-EXPRESSION | RESISTANCE | COMBINATION CHEMOTHERAPY | RAF/MEK/ERK PATHWAY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Predictive Value of Tests | Extracellular Signal-Regulated MAP Kinases - blood | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | RNA, Neoplasm - blood | Benzenesulfonates - adverse effects | Liver Neoplasms - blood | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Carcinoma, Hepatocellular - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2012, Volume 118, Issue 21, pp. 5293 - 5301
BACKGROUND: This study explored the efficacy, tolerability, and survival benefits of using sorafenib in patients with Child‐Pugh class B (CPB) cirrhosis.... 
Child‐Pugh A | advanced hepatocellular carcinoma | adverse events | sorafenib | Child‐Pugh B | BAY-43-9006 | SAFETY | STAGE | RAF KINASE | Child-Pugh B | Child-Pugh A | FACTOR RECEPTOR INHIBITOR | PHARMACOKINETICS | ONCOLOGY | REFRACTORY SOLID TUMORS | PHASE-I
Journal Article
Journal Article
by Tong, J and Tan, S and Zou, F and Yu, J and Zhang, L
Oncogene, ISSN 0950-9232, 02/2017, Volume 36, Issue 6, pp. 787 - 796
Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of... 
UBIQUITIN LIGASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOWN-REGULATION | SORAFENIB | MULTIKINASE INHIBITOR | CELL CARCINOMA | INHIBITOR BAY-43-9006 | CELL BIOLOGY | APOPTOTIC RESPONSE | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | GENETICS & HEREDITY | PHASE-3 TRIAL | TUMOR-SUPPRESSOR | Niacinamide - analogs & derivatives | F-Box-WD Repeat-Containing Protein 7 | Colorectal Neoplasms - genetics | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Drug Resistance, Neoplasm | Mutation, Missense | Molecular Targeted Therapy | Heterografts | Transfection | Colorectal Neoplasms - drug therapy | Cell Cycle Proteins - genetics | Female | Colorectal Neoplasms - metabolism | F-Box Proteins - metabolism | HCT116 Cells | Cell Cycle Proteins - metabolism | Ubiquitin-Protein Ligases - metabolism | Gene Knockout Techniques | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Animals | Mice, Nude | Cell Line, Tumor | Mice | Phenylurea Compounds - pharmacology | Pyridines - pharmacology | Niacinamide - pharmacology | Colorectal Neoplasms - pathology | Ubiquitin-Protein Ligases - genetics | F-Box Proteins - genetics | Ubiquitin | Care and treatment | Gene mutations | Colorectal cancer | Tumor suppressor genes | Genetic aspects | Research | Health aspects | Genetics | Mutation | Cellular biology | Drug resistance | Targeted cancer therapy | Mcl-1 | apoptosis | colorectal cancer | targeted therapies | FBW7
Journal Article